BIFIDO Co. Ltd (238200) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIFIDO Co. Ltd (238200) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-31.26 Million ≈ $-21.19K USD) by net assets (₩44.44 Billion ≈ $30.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of BIFIDO Co. Ltd to measure how much of total assets are equity-financed.
BIFIDO Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how BIFIDO Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BIFIDO Co. Ltd (238200) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
BIFIDO Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIFIDO Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Denali Capital Acquisition Corp. Class A Ordinary Shares
NASDAQ:DECA
|
0.008x |
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
-9.243x |
|
Chinyang Poly
KO:010640
|
0.004x |
|
Auris Minerals Ltd
AU:AUR
|
-0.017x |
|
MMS Ventures Bhd
KLSE:0113
|
-0.026x |
|
Koonenberry Gold Ltd
AU:KNB
|
-0.040x |
|
Senior PLC
LSE:SNR
|
0.147x |
|
Salona Cotspin Limited
NSE:SALONA
|
0.248x |
Annual Cash Flow Conversion Efficiency for BIFIDO Co. Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of BIFIDO Co. Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is BIFIDO Co. Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩45.93 Billion ≈ $31.13 Million |
₩3.95 Billion ≈ $2.68 Million |
0.086x | +660.57% |
| 2024-12-31 | ₩46.69 Billion ≈ $31.64 Million |
₩-716.29 Million ≈ $-485.42K |
-0.015x | -127.85% |
| 2023-12-31 | ₩51.70 Billion ≈ $35.04 Million |
₩2.85 Billion ≈ $1.93 Million |
0.055x | +54.19% |
| 2022-12-31 | ₩52.49 Billion ≈ $35.57 Million |
₩1.88 Billion ≈ $1.27 Million |
0.036x | -11.12% |
| 2021-12-31 | ₩50.64 Billion ≈ $34.32 Million |
₩2.04 Billion ≈ $1.38 Million |
0.040x | -3.97% |
| 2020-12-31 | ₩44.60 Billion ≈ $30.22 Million |
₩1.87 Billion ≈ $1.27 Million |
0.042x | -26.86% |
| 2019-12-31 | ₩46.29 Billion ≈ $31.37 Million |
₩2.65 Billion ≈ $1.80 Million |
0.057x | -46.13% |
| 2018-12-31 | ₩44.73 Billion ≈ $30.31 Million |
₩4.75 Billion ≈ $3.22 Million |
0.106x | -49.13% |
| 2017-12-31 | ₩18.50 Billion ≈ $12.53 Million |
₩3.86 Billion ≈ $2.62 Million |
0.209x | +0.49% |
| 2016-12-31 | ₩16.07 Billion ≈ $10.89 Million |
₩3.34 Billion ≈ $2.26 Million |
0.208x | -- |
About BIFIDO Co. Ltd
BIFIDO Co., Ltd. produces probiotics-based products in South Korea and internationally. It offers bifidobacterium strain products, such as BGN4 for immune modulating; BORI used to treat rotavirus infection in infants; and AD011 for general intestinal health problems. The company was founded in 1999 and is headquartered in Hongcheon-eup, South Korea.